Agendia, Inc. Provides Review of Successful 2024

Contributed by: Business Wire

Logo

Images

Personalized biology-based insights (Graphic: Business Wire)

Business Wire embedded0

Tags

Oncology

Health

Medical Devices

Genetics

Clinical Trials

Pharmaceutical

Biotechnology

2024 Topline Review

More Like This

Agendia Achieves CE-IVDR Certification for its MammaPrint® and BluePrint® Breast Cancer Assays

(Graphic: Business Wire)

Agendia Announces Publication Validating MammaPrint® Utility in Prediction of Extended Endocrine Therapy Benefit

Immunovia Publishes Full Year Report for 2023

PR Newswire associated0

MGI: Closing the Cancer Care Gap with the Power of Precision Oncology

Immunovia Publishes Interim Report for January-June 2024

Immunovia Publishes Interim Report for January-September 2023

Immunovia Publishes Interim Report for January-March 2024

Exact Sciences Demonstrates Continued Leadership in Early Cancer Diagnosis and Improved Health Outcomes for Patients with Multiple Data Presentations at ASCO®